C4 Therapeutics, Inc.

It’s National #STEM Day! As catalysts in the field of #TPD, we take inspiration from collaboration, sparking each other’s ideas to advance our science and accelerate our collective impact on patients, including early career colleagues who are interested in paving a path in STEM. Our team takes pride in sharing our love of science to the future catalysts of the world, including through our annual Project Onramp internship program. We encourage anyone interested in STEM to pursue this impactful career! #NationalSTEMDay

#TPD program update: We announced that our partner Betta Pharmaceuticals Co., Ltd. has dosed the first patient in the Phase 1 clinical trial of CFT8919, an orally bioavailable degrader of #EGFR L858R in non-small cell lung cancer (#NSCLC), in Greater China.     C4T designed CFT8919 to target EGFR mutations in NSCLC, which are particularly common in NSCLC patients of Asian heritage. Our team is thrilled to see this therapy enter clinical development. Learn more in our latest release: https://bit.ly/3YABPeQ

At the American Society of Hematology’s (ASH) Annual Meeting in December we will present data from the ongoing Phase 1/2 trial of our orally bioavailable MonoDAC® degrader, cemsidomide, in multiple #myeloma and non-Hodgkin’s #lymphoma. Learn more in our latest release: https://bit.ly/3UCAFyr #ASH24

Find us at the ASAP BioPharma Conference in Boston! Our SVP of strategic alliances and business development, Isabel Chiu, and Susan Green, executive director and head of R&D strategic collaborations at Biogen, will present on our #TPD collaboration to develop new treatments for patients. More on the event here: https://bit.ly/4f3Yrvp

We announced third quarter 2024 financial results and recent business highlights. Read more here: https://bit.ly/40rUsV4

Our team is at the #TPD and Induced Proximity Summit in Boston to deliver presentations on our leadership in developing highly catalytic orally bioavailable degraders and participate in panel discussions with our industry colleagues on topics like the state of the TPD field and best practices in managing strategic partnerships. Learn more: https://bit.ly/3tHso1l  

The C4T team is thrilled to welcome Paige Mahaney, Ph.D., as our newest chief scientific officer! Paige will be instrumental in leading innovation and pushing the boundaries of what is possible for #TPD as we explore opportunities to extend our leadership in the field. Paige comes to C4T with more than 25 years of pharmaceutical and biotech experience in overseeing drug discovery, expanding clinical portfolios at major pharmaceutical companies and building platforms for a wide range of disease indications and treatment modalities, including degraders. We can't wait to witness all that Paige does to accelerate our science! Learn more about this news in our latest release: https://lnkd.in/erX4W6P9

Today we announced the appointment of Paige Mahaney as chief scientific officer following the decision of Stewart L. Fisher, Ph.D. to retire and pursue personal interests. Learn more in our latest release: https://bit.ly/48prN4Z

C4 Therapeutics was named a 2024 BostInno Fire Awards honoree! The BostInno Fire Awards recognize 50 companies, organizations or people who have had success over the past year in supporting our community and growing the local innovation ecosystem.    C4T was recognized for expanding its pharmaceutical partnerships, advancing two #TPD programs through early-stage clinical trials and appointing new leaders who will guide the company to develop a new generation of medicines. Read the full list here: https://bit.ly/3XUXBK0 Boston Business Journal #INNOFIRE 

We are looking forward to the TPD and Induced Proximity Summit, happening between October 28-31 in Boston. Members of our leadership team will deliver oral presentations to highlight our leadership in designing and developing highly catalytic orally bioavailable degraders that have the potential to transform patients’ lives. We’ll also participate in multiple expert panel discussions spanning topics including taking a broad look at the state of the #TPD field and managing strategic partnerships for both platforms and discovery assets. Learn more about C4T’s presence at the event in our latest release: https://bit.ly/3XXqTYu